Efficacy of a Low-cost Warming Mattress Celsi Warmer for the Management of Hypothermic Newborns at Muhimbili National Hospital, Dar es Salaam, Tanzania

Neonatal Hypothermia Clinical Trial

Official title:

Efficacy of a Low-cost Warming Mattress Celsi Warmer for the Management of Hypothermic Newborns at Muhimbili National Hospital, Dar es Salaam, Tanzania

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05876884
• Other study ID #: TZ Celsi Warmer
• Status: Recruiting
• Phase: N/A
• Start date: August 1, 2022
• Est. completion date: August 20, 2024

Study information

• Verified date: May 2023
• Source: William Marsh Rice University
• Contact: Rebecca Massey, MPH, BSN, RN
• Phone: 7133482923
• Email: rebecca.elias[@]rice.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The prevalence of hypothermia across low-resource settings is high, especially in countries with high neonatal mortality rates. If left untreated, hypothermia can additionally result in a significant comorbidity, and has been linked to a reduction in the effectiveness of treatment for other newborn conditions. Thermal care for hypothermic newborns is not widely available in low-resource settings due to cost, and lack of consumables and spare parts. In this study, the research team will evaluate the efficacy of a novel neonatal warming mattress intreating hypothermic newborns. The warming mattress, 'Celsi Warmer', has been developed by Rice360 Institute for Global Health Technologies, in conjunction with African clinicians, to be a robust, low-cost, and easy-to-use warming mattress which can address the challenges of hypothermia. This is a single-arm, non-randomized, prospective intervention study. Up to90eligible infants at Muhimbili National Hospital (MNH) at Upanga Neonatal Unit will be recruited to evaluate the efficacy of Celsi Warmer in rewarming hypothermic newborns. Infants temperature will be monitored during thermal intervention and the performance of the device will be evaluated. The temperatures of each infant will be compared before, during, and after the intervention.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: August 20, 2024
• Est. primary completion date: August 20, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 0 Days to 28 Days

Eligibility

Inclusion Criteria:

Any neonate who:

1. Is currently being treated at study location

2. Is an inborn admission to the neonatal ward

3. Whose parents or guardians provided a written informed consent

4. Whose parents or guardians providing informed consent are 18 years old or older

5. Has a current weight of greater than or equal to 1.0 kg and less than or equal to 4.0kg

6. Has been identified as in need of thermal care defined as having a moderate hypothermic temperature (32.0-36.0°C) as the last temperature recorded in hospital chart, or during recruitment procedures; and

7. Is unable to be enrolled in Kangaroo Mother Care (KMC) for reasons including, but not limited to: a.Mother/guardian unable or unavailable to provide KMC b.Under observation in NICU before transfer to KMC c.No space in KMC d.Clinician's discretion

8. May be receiving other medical treatments, including but not limited to, CPAP, oxygen therapy, IV fluids, management and monitoring of common newborn conditions such as hypoglycemia, and/or hyperbilirubinemia via LED phototherapy The study will not interfere with any other treatment being provided at the ward, and it will not delay the participant from transferring to KMC or being discharged Exclusion Criteria:

Any neonate who:

1. Requires mechanical ventilation

2. Is deemed in need of intensive care by the hospital staff who is providing care,including but not limited to: a.neonates with severe anemia and/or any suspected hematological disorders, and/or b. Neonates with obvious congenital anomalies, and/or c.neonates suspected with hypo/hyperthyroidism or any hormonal disorders

3. Has been diagnosed with birth asphyxia

4. Presents a condition that precludes the use of the temperature sensor and/or abdominal belt including but not limited to, gastroschisis, known umbilical cord infection, known skin infection

5. Whose clinician presents concerns about their participation

6. Is receiving treatment that participation in the study would interfere with, i.e.transferring to KMC

Related Conditions & MeSH terms

• Hypothermia
• Neonatal Hypothermia

Intervention

Device:
• Celsi Warmer Mattress
The hypothermic neonate will be placed on the Celsi Warmer mattress and a temperature probe will be placed on the neonate to monitor the temperature of the neonate for up to 24 hours of intervention time

Locations

Country	Name	City	State
Tanzania	Muhimbili National Hospital	Dar Es Salaam

Sponsors (4)

Lead Sponsor	Collaborator
William Marsh Rice University	Ifakara Health Institute, Ministry of Health, Community Development, Gender, Elderly, and Children (MOHCDGEC), Muhimbili University of Health and Allied Sciences

Country where clinical trial is conducted

Tanzania, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Broad Objective	To evaluate the clinical efficacy and safety of the Celsi Warmer in rewarming hypothermic newborns by comparing the Celsi Warmer's accuracy in measuring neonatal temperature compared to the gold standard, axillary temperature readings.	1 year
Secondary	Efficacy of the Device	To assess the performance of the Celsi Warmer in rewarming hypothermic newborns by measuring the incidence of attainment of normothermia (36.5-37.5°C)	1 year
Secondary	Safety of Device	To measure the infant's rate of temperature (°C) increase through thermoregulatory intervention.	1 year
Secondary	Safety of Device	To evaluate the local effect of the abdominal belt on newborn's skin by looking at any evidence of skin irritation	1 year
Secondary	Safety of Device	To evaluate any incidence of hyperthermia (>37.5°C) during the thermoregulation intervention.	1 year
Secondary	Safety of Device	To report any incidence of rebound hypothermia ( < 36.5°C) (post-intervention hypothermia) up to 72 hours from the initial encounter	1 year